Advertisement

Struma maligna pp 313-318 | Cite as

Rationale der Radiojodtherapie des differenzierten Schilddrüsenkarzinoms

  • R. Höfer
  • J. Flores
  • M. Weissel
Conference paper

Zusammenfassung

Obwohl das Schilddrüsenkarzinom eine seltene Krebserkrankung ist [6, 13], kommt ihm klinisch hohe Bedeutung zu, weil radioaktives Jod ein hochspezifisches Therapeutikum der differenzierten Karzinome darstellt. Es ist heute allgemein anerkannt, daß differenzierte Schilddrüsenkarzinome — der Primärtumor, das Lokalrezidiv und auch Fernmetastasen — mit radioaktivem Jod sehr erfolgreich behandelt werden können.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Blahd WH (1979) Treatment of malignant thyroid diseases. Semin Nucl Med 9:95PubMedCrossRefGoogle Scholar
  2. 2.
    Crile G Jr (1966) Endocrine dependence of papillary carcinoma of the thyroid. J Am Med Assoc 195:721CrossRefGoogle Scholar
  3. 3.
    Dralle H, Robin-Winn M, Reilmann L, Laue A, Török M (1986) HLA und Schilddrüsenkarzinom. Klin Wochenschr 64:522PubMedCrossRefGoogle Scholar
  4. 4.
    Duffy BJ Jr, Fitzgerald PJ (1950) The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine. Clin Endocrinol 10:1296CrossRefGoogle Scholar
  5. 5.
    Edmonds CJ, Smith T (1986) The long term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59:45PubMedCrossRefGoogle Scholar
  6. 6.
    Freitas JE, Gross MD, Ripley S, Shapiro B (1985) Radionuclide diagnosis and therapie of thyroid cancer. A current status report. Semin Nucl Med 15:106PubMedCrossRefGoogle Scholar
  7. 7.
    Goolden AWG (1985) The indications of ablating normal thyroid tissue with 131I in differentiated thyroid cancer. Clin Endocrinol 23:81CrossRefGoogle Scholar
  8. 8.
    Juhasz F, Balasz G, Stenszky V, Kozma L, Farid NA (1986) The relation of susceptibility to an biological behavior of thyroid epithelial cell cancer to HLA-DR1. Cancer 58:52PubMedCrossRefGoogle Scholar
  9. 9.
    Leepper RD, Shimaoka K (1980) Treatment of metastatic thyroid cancer. Clin Endocrinol Metab 9:383CrossRefGoogle Scholar
  10. 10.
    Mazzaferri EL, Young RL (1981) Papillary thyroid carcinoma: a 10 years follow-up report of the impact of therapy in 576 patients. Am J Med 70:511PubMedCrossRefGoogle Scholar
  11. 11.
    Panza N et al (1982) Strong association between an HLA-DR antigen and thyroid carcinoma. Tissue Antigens 20:155PubMedCrossRefGoogle Scholar
  12. 12.
    Pochin EE (1969) Long-term hazards of radioiodine treatment of thyroid carcinoma. In: Hedinger C (ed) Thyroid cancer, vol XII. UICC Monogr Ser. Springer, Berlin Heidelberg New York, p 293Google Scholar
  13. 13.
    Pochin EE (1977) Diagnosis of thyroid carcinoma. In: Hoefer R et al. (eds) Rational diagnosis of thyroid disease. Egermann, Wien, p 187Google Scholar
  14. 14.
    Reiners C, Reimann J, Rendl J, Boerner W (1986) Prognosis of thyroid carcinoma using the WEIBULL function for calculation of a prognostic index and its relevance for follow-up protocols. Nucl Med 25:A21Google Scholar
  15. 15.
    Samaan NA et al. (1983) Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 56:1131PubMedCrossRefGoogle Scholar
  16. 16.
    Sridama V, Hara Y, Fauchet R, De Groot LJ (1985) Association of differentiated thyroid carcinoma with HLA-DR7. Cancer 56:1086PubMedCrossRefGoogle Scholar
  17. 17.
    Weissei M, Bergmann H, Steidler B (1983) Struma maligna. Retrospective Analyse des Patientengutes und der Behandlungsergebnisse der Nuklearmedizinischen Abteilung der II. Medizinsichen Universitätsklinik Wien von 1973 bis 1982. Acta Med Austriaca 10:83Google Scholar
  18. 18.
    Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG (1980) Pure follicular carcinoma: impact of therapy in 24 patients. J Nucl Med 21:733PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • R. Höfer
  • J. Flores
  • M. Weissel

There are no affiliations available

Personalised recommendations